Vitrafy Life Sciences Ltd. · ASX:VFY
Vitrafy Life Sciences — NWR Virtual Healthcare Conference 2025
32 slides from Vitrafy Life Sciences's conference presentation, Mar 20, 2025
Slide 1: ASX Announcement: NWR Virtual Healthcare Conference Presentation
ASX ANNOUNCEMENT 20 March 2025 NWR Virtual Healthcare Conference Presentation Vitrafy Life Sciences Limited (ASX: VFY), (Vitrafy or Company) advises that Deputy CEO & Executive Director, Brent Owens will deliver the attached presentation at the NWR Virtual Healthcare Conference today. ### ENDS ### F
Slide 2: NWR Investor Conference Investor Presentation
For personal use only NWR Investor Conference Investor Presentation VFY.ASX PRESERVING LIFE Improving the quality of healthcare treatments by providing effective cryopreservation solutions March 2025
Slide 3: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation is provided by Vitrafy Life Sciences Limited (ACN 622 720 254) (the Company). Statements in this The distribution of this presentation may be restricted by law. Persons who come into possession of this presentation presentation are made only as at the
Slide 4: Important Notice & Disclaimer (cont.)
Important Notice & Disclaimer (cont.) Not financial product advice All figures in the presentation are Australian dollars ($ or A$) unless stated otherwise. A number of figures, amounts, Reliance should not be placed on the information or opinions contained in this presentation. This presentation is
Slide 5: Vitrafy addresses the vital global need for enhanced cryopreservation solutions
Vitrafy addresses the vital For personal use only global need for enhanced cryopreservation solutions. Vitrafy’s mission is to improve the quality of healthcare treatments by providing effective cryopreservation technology, preserving life. 4
Slide 6: Company Overview
For personal use only 1 Overview Company 5
Slide 7: Executive Summary
Executive Summary Vitrafy is an Australian based, end-to-end cryopreservation technology provider that is on a mission to become the global leader in cryopreservation and set new industry quality standards for cryopreserved materials, ultimately helping preserve life. For personal use only Innovativ
Slide 8: Vitrafy – A New Standard of Quality
Vitrafy – A New Standard of Quality Vitrafy’s cryopreservation technology integrates software and hardware solutions to deliver quality outcomes. For personal use only Sample quality retention software platform \ Patient - Sample Sample Preparation Deep Freeze Application (e.g. Collection Storage &
Slide 9: Vitrafy's Value Proposition
Vitrafy’s Value Proposition Vitrafy has a clear and focused mission to become the global leader in cryopreservation by significantly improving the cell survival of cryopreserved biological materials when compared to existing industry standards. For personal use only Third-party validated quality ret
Slide 10: Vitrafy History
Vitrafy History Founded in 2017, Vitrafy set out to redefine quality outcomes for cryopreserved biological materials, globally. For personal use only PHASE 1 PHASE 2 PHASE 3 PHASE 4 (2017 – 2020) (2021 – 2023) (2023 – 2024) (2024 AND BEYOND) Vitrafy Founded and Value Positioning Collaborations and P
Slide 11: Outlook
Outlook With short term milestones ahead, Vitrafy remains focused and clear on deliverables towards executing on its mission to become the global leader in cryopreservation, preserving life. For personal use only H2 FY25 Establishing US presence and personnel Progressing the pipeline of business dev
Slide 12: Cryopreservation Environment
For personal use only 2 Cryopreservation Environment 11
Slide 13: What is Cryopreservation?
What is Cryopreservation? Cryopreservation preserves biological materials by cooling samples to very low temperatures for future use. Quality cryopreservation improves availability, quality and consistency for life-saving therapeutic treatments. For personal use only Standard Cryopreservation Supply
Slide 14: Existing Supply Chain Management is Sub-standard
Existing Supply Chain Management is Sub-standard Vitrafy has a clear and focused mission to become the global leader in cryopreservation by significantly improving the cell For personal use only survival of cryopreserved biological materials when compared to existing industry standards. ( J U L Y 2
Slide 15: Vitrafy's Technology Solution
For personal use only 3 Vitrafy’s Technology Solution 14
Slide 16: LifeChain
LifeChain TM LifeChain sample quality management software is focused on retaining the quality of biological material across the entire cryopreservation supply chain. • LifeChain is a simple user-friendly software and interface that automatically collects, calculates, trends and monitors data while i
Slide 17: Vitrafy's Smart Devices
Vitrafy’s Smart Devices Vitrafy has a suite of smart medical devices and consumables For personal use only SMART FREEZING DEVICE (VCU1) SMART THAWING DEVICE (VTU1) SMART CONSUMABLES • Controlled cryopreservation • Controlled thawing • Smart blood bags • Portable • Precise protocols • Smart sperm pac
Slide 18: Vitrafy's Cryopreservation Software and Hardware Solution
Vitrafy’s Cryopreservation Software and Hardware Solution 1st Generation Freezing (VCU1) For personal use only 2nd Generation Thawing (VTU2) 1st Generation Thawing (VTU1) 2nd Generation Freezing (VCU2) Note: These are concept-only images. 2nd Generation devices are currently in the development stage
Slide 19: For personal use only
For personal use only Note: These are concept-only images. 2nd Generation devices are currently in the development stage 18
Slide 20: VCU1 > VCU2
VCU1 > VCU2 VCU2 will retain all core functionality and principles of VCU1, whilst improving core areas that enable a more portable, flexible, automated and profitable device. For personal use only VCU2 Usability best practice through automation Increased reliability through refrigeration system opt
Slide 21: Commercialisation
For personal use only 4 Commercialisation 20
Slide 22: Vitrafy Commercialisation Strategy
Vitrafy Commercialisation Strategy Under a collaboration-to-commercialisation strategy, Vitrafy has a partnered with key market leaders in priority application areas to educate the market and drive adoption. For personal use only Strategy COLLABORATION – TO – COMMERCIALISATION Validate Cryopreservat
Slide 23: Revenue Case Study – Salmon Aquaculture
Revenue Case Study – Salmon Aquaculture Vitrafy has proven out the commercial model in salmon aquaculture and is preparing to scale in FY25 and beyond. HUON AQUACULTURE – REVENUE CASE STUDY ANIMAL BREEDING & AQUACULTURE MARKET – US$7.8 BILLION2 For personal use only Ovine • In September 2022, Huon A
Slide 24: Execution Pipeline
Execution Pipeline Vitrafy has partnered with key strategic groups via collaboration agreements to assist with in fast-tracking its commercialisation process. For personal use only COLLABORATION PARTNERS Blood and Blood Products with US Army Bovine Sperm with Select Sires Inc Cell and Gene Therapy w
Slide 25: Board and Management
For personal use only 5 Board and Management 24
Slide 26: Board and Senior Management
Board and Senior Management The Board and Senior Management bring relevant experience, including sector and business knowledge, financial management and corporate governance experience. For personal use only Sonia Petering Kate Munnings Brent Owens Independent Chair & Chief Executive Officer & Deput
Slide 27: Thank you
Thank you For personal use only Contacts Mrs. Kathryn (Kate) Munnings Mr. Brent Owens Chief Executive Officer & Deputy Chief Executive Officer, Managing Director Co-Founder & Executive Director Email: kmunnings@vitrafy.com Email: bowens@vitrafy.com Simon Martin Michael Sapountzis Chief Financial Off
Slide 28: A1 Market & Growth Opportunity
For personal use only A1 Market & Growth Opportunity 27
Slide 29: Large Addressable Markets
Large Addressable Markets Vitrafy’s total addressable market is anticipated to grow at a CAGR of 10.6% to reach US$185 billion by 2030 underpinned by favorable tailwinds. For personal use only 2030 TOTAL ADDRESSABLE MARKET1 MARKET DRIVERS Animal Breeding & Aquaculture Change in environmental stand
Slide 30: Applications of Vitrafy's Cryopreservation Technology
Applications of Vitrafy’s Cryopreservation Technology Vitrafy’s Cryopreservation Technology has widespread applications across a variety of biological materials. For personal use only ADDRESSABLE ANIMAL BREEDING & AQUACULTURE BLOOD PLATELETS HUMAN CELL & GENE THERAPY MARKETS Pharmaceutical companies
Slide 31: Strategy and Competitive Advantage
Strategy and Competitive Advantage Vitrafy is focusing on three priority application areas where our Cryopreservation Technology will yield the greatest benefit. For personal use only PRIORITY AQUACULTURE & HUMAN CELL & BLOOD PLATELETS APPLICATION AREA BOVINE REPRODUCTION GENE THERAPY Regulatory Unr
Slide 32: Target Customers and Commercial Opportunity
Target Customers and Commercial Opportunity The three priority application areas Vitrafy is immediately focusing on represent significant commercial opportunities where Vitrafy has a clear competitive advantage For personal use only PRIORITY AQUACULTURE & HUMAN CELL & BLOOD PLATELETS APPLICATION ARE
Vitrafy Life Sciences — NWR Virtual Healthcare Conference 2025 on 6ix